Does Oxytocin Alter Tolerance to or Motivation for Alcohol
Key facts
- Who runs it
- Indiana University
- Where
- Indianapolis, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 2
- People taking part
- 6 people enrolled
- Started
- 16 Jan 2022
- Ended
- 21 Dec 2023
- Type of study
- Interventional, 2 groups
- Treatments tested
- Intranasal oxytocin
- Intranasal placebo
- Record updated
- 4 March 2025
- Why it stopped
- Due to complications delaying the availability of the intranasal oxytocin and IV alcohol solutions needed for this project, we were unable to complete subjects in the self-administration arm of this study.
Who can take part
- Age
- 21 years to 60 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Heavy alcohol drinkers
- Able to understand/complete questionnaires and procedures in English
- Have venous access sufficient to allow blood sampling
Who cannot take part
- Positive urine drug screen for amphetamines/ methamphetamines, barbiturates, benzodiazepines, cocaine, opiates, or phencyclidine if determined by the PI to adversely affect participant safety or data integrity
- Medications (past 30 days) that could influence participant safety or data integrity (e.g. antidepressants, antipsychotics, benzodiazepines, etc.) as determined by the PI
- Latex allergy
- Nasal condition that compromises delivery and/or absorption of intra-nasal oxytocin
- Desire to be treated for any substance use disorder or court ordered to not drink alcohol
- Medical disorders or other conditions such as alcohol withdrawal seizures or delirium tremens that may influence study outcome or participant safety
- DSM 5 Disorders (other than alcohol) or current/history of neurological disease of cerebral origin, or head injury with > 20 min loss of consciousness, if determined by the PI to affect participant safety or data integrity
- Any condition for which the PI and investigative team determine it is unsafe or not prudent to enroll a participant
- Pregnant or breast-feeding women
- Positive breath alcohol reading at beginning of the experimental session
- Actively suicidal (for example, any current suicidal intent, including a plan) or are at serious suicidal risk, by clinical judgment of the PI
Where in United States
- University HospitalIndianapolis, United States
About the trial
What the trial wants to find out
This pilot study is intended to demonstrate feasibility and acquire preliminary data. If successful, this data could support a future project studying the effect of oxytocin on tolerance and alcohol seeking in humans.
The 2 groups in the trial
- ClampTreatment being tested
Repeated subjective and cognitive tests during a 4 hour session that includes a baseline period, an oxytocin or placebo delivery, absorption and testing period, and a 2 hour alcohol clamp. Oxytocin or placebo were delivered intranasally in two sessions, scheduled 3-4 weeks apart, double blind.
Treatment: Intranasal oxytocin and Intranasal placebo
- Progressive work for alcoholTreatment being tested
Progressive work alcohol exposure, 2 sessions (intranasal oxytocin or placebo), double blind. Note this Arm was not completed (see Overall Status for explanation of study termination)
Treatment: Intranasal oxytocin and Intranasal placebo
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Does Oxytocin Alter Tolerance to Alcohol or Motivation for Alcohol in Heavy Drinking Human Subjects: Testing a Novel Anti-Addiction Mechanism
- Record updated
- 4 March 2025